Pharmakotherapie der Zwangsstörung

In der Behandlung der Zwangsstörung gilt derzeit die (kognitive) Verhaltenstherapie als Mittel der ersten Wahl. In Kombination oder im Anschluss an eine Psychotherapie ist jedoch oft der Einsatz von Medikamenten unumgänglich. Antidepressiva mit spezifisch serotonergen Wirkmechanismus haben sich dabei gut etabliert. Ihre wissenschaftliche Evidenz und ihr besonderer Einsatz bei Zwangsstörungen werden im Folgenden referiert. Aufgrund der oft schweren, therapierefraktären Verläufe der Zwangserkrankung wurden in der Vergangenheit auch viele weitere medikamentöse Strategien verfolgt – diese werden ebenfalls auf ihre empfohlene Anwendbarkeit überprüft.

• Literatur

• 1 Baumgarten HG, Grozdanovic Z. Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry 1998; 35: 13-20
• 2 Bogan AM, Koran LM, Chuong HW et al. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 2005; 66: 73-79
• 3 Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004; 65: 565-568
• 4 Chamberlain SR, Blackwell AD, Fineberg NA et al. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005; 29: 399-419
• 5 Cottraux J, Bouvard MA, Milliery M. Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn Behav Ther 2005; 34: 185-192
• 6 Denys D. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23: 568-575
• 7 Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004; 65: 7-11
• 8 Denys D, Mantione M, Figee M et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2010; 67: 1061-1068
• 9 DGPPN Hrsg S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. Berlin/Heidelberg: Springer; 2012
• 10 DGPPN Hrsg. S3-Leitlinie Zwangsstörungen. Im Internet: http://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/kurzversion-leitlinien/S3-Leitlinie_Zwangsst%C3%B6rungen_lang.pdf ); Stand: 14.05.2013
• 11 Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005; 8: 107-129
• 12 Greenberg BD, Gabriels LA, Malone DA et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 2010; 15: 64-79
• 13 Greist JH, Bandelow B, Hollander E. World Council of Anxiety. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 2003; 8: 7-16
• 14 Hesse S, Stengler K, Regenthal R, Patt M et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2011; 14: 606-617
• 15 Hollander E, Koran LM, Goodman WK et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003; (a) 64: 640-647
• 16 Hollander E, Allen A, Steiner M et al. Paroxetine OCD Study Group. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003; (b) 64: 1113-1121
• 17 Huppert JD, Franklin ME. Cognitive behavioral therapy for obsessive-compulsive disorder: an update. Curr Psychiatry Rep 2005; 7: 268-273
• 18 Jenike MA, Baer L, Summergrad P et al. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry 1989; 146: 1328-1330
• 19 Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990; 28: 401-414
• 20 Komossa K, Depping AM, Meyer M et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev 2010; 12 CD008141
• 21 Lesch KP, Osterheider M, Wiesmann M et al. Sensitivität des prä- und postsynaptischen 5-HT1A-Receptors bei Zwangskrankheit. In: Gaebel W, Laux G. Hrsg Biologische Psychiatrie. Berlin: Springer; 1992: 413-418
• 22 Li X. Risperidone and Haloperidol augmentation of serotoninreuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005; 66: 736-743
• 23 Lochner C, Stein DJ. Heterogeneity of obsessive-compulsive disorder: a literature review. Harv Rev Psychiatry 2003; 11: 113-132
• 24 Mantovani A, Simpson HB, Fallon BA et al. Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistent obsessive-compulsive disorder. Int J Neuropsychopharmacol 2010; 13: 217-227
• 25 Matsunaga H, Nagata T, Hayashida K et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009; 70: 863-868
• 26 Pallanti S, Hollander E, Bienstock C et al. International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5: 181-191
• 27 Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004; 65: 6-10
• 28 Reynghe de Voxrie GV. Anafranil (G34586) in obsessive neurosis. Acta Neurol Psychiatr Belg 1968; 68: 787-792
• 29 Rodriguez-Martin JL, Barbanoj JM, Pérez V, Sacristan M. Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst Rev 2003; 3 CD003387
• 30 Rosenberg DR, Keshavan MS. Toward a neurodevelopmental model of of obsessive--compulsive disorder. Biol Psychiatry. 1998; 43: 623-640
• 31 Soomro GM. Obsessive compulsive disorder. Clin Evid (Online) 2007; pii:1004
• 32 Stein DJ. Obsessive-compulsive disorder. Lancet 2002; 360: 397-405
• 33 Stengler-Wenzke K, Müller U, Barthel H et al. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder. Neuropsychobiology 2006; 53: 40-45
• 34 Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169: 468-474